BIOA: BioAge Labs, Inc. Company Short-Term Debt

Symbol and logo of brand BioAge Labs, Inc. (BIOA)

Investing in BioAge Labs, Inc. (BIOA) carries the risk of failure in anti-aging drug testing and significant R&D expenditures. Simultaneously, the business relies on an autonomous development cycle, providing the asset with defensive qualities against global crises. BioAge Labs, Inc. (BIOA) develops metabolic correction drugs, and the indicator stands at 0.00. This chart of short-term liability value changes reveals the issuer's debt dynamics.

BIOA (BioAge Labs) Company Short-Term Debts history from 09/27/2024 to 10/30/2026

BIOA (BioAge Labs, Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart BioAge|BIOA - Fair Value Consensus
- market capitalization information:
Market Value BioAge|BIOA - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share BioAge Labs, Inc.|BIOA - Book Capitalization|Market Cap to Net Assets Ratio bioagelabs.com|BIOA - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity BioAge Labs, Inc.|BIOA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital BioAge Labs, Inc.|BIOA - Company Cumulative Debt|Debt to Book Value BioAge|BIOA - Amount of Long-Term Liabilities|Company Short-Term Debts BioAge Labs, Inc.|Quick Ratio bioagelabs.com
- net income and valuation multiples indicators:
BIOA - Company Net Income
Basic company analysis:BioAge - BIOA
Mass-produced product of BioAge Labs, Inc

Liquidity control is critical for BioAge Labs, Inc. (BIOA), which is developing a costly pipeline of anti-obesity drugs. This metric aggregates all obligations maturing within one year, reflecting the current debt load. Analyzing the level of short-term loans allows for an assessment of the risk of cash flow gaps when financing clinical trials. An increase in this metric signals pressure on capital, while a decrease indicates financial stability. This determines the overall solvency of the issuer.

Who BioAge Labs, Inc. competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Aardvark Therapeutics Inc. (AARD) - Short-Term Debt|SGMT - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debts LPCN (Lipocine Inc.)|Matinas BioPharma Holdings, Inc. - Company Short-Term Debt|Spruce Biosciences - Company Short-Term Debts|Short-Term Debt Volume Galecto Inc GLTO|Carmell Corp (CTCX) - Company Short-Term Debt|Short-Term Debt Lumos Therapeutics (LUMO)|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|Company Short-Term Debts radiuspharm.com